Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/788920/000155335020000128/pdex_10q.htm
August 2022
May 2022
February 2022
December 2021
December 2021
November 2021
November 2021
November 2021
September 2021
August 2021
Document and Entity Information - shares | 6 Months Ended | |
---|---|---|
Dec. 31, 2019 | Feb. 04, 2020 | |
Document And Entity Information | ||
Entity Registrant Name | PRO DEX INC | |
Entity Central Index Key | 0000788920 | |
Document Type | 10-Q | |
Document Period End Date | Dec. 31, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --06-30 | |
Entity's Reporting Status Current | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 3,872,756 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2020 | |
Entity Incorporation State Country Code | CO | |
Entity File Number | 0-14942 |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/788920/000155335020000128/pdex_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Pro Dex Inc.
Pro Dex Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
15 An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements.
18 Research and development costs generally consist of salaries, employer paid benefits, and other personnel related costs of our engineering and support personnel, as well as allocated facility and information technology costs, professional and consulting fees, patent-related fees, lab costs, materials, and travel and related costs incurred in the development and support of our products.
Although we experienced an influx of cash in the amount of $1.4 million in collections from receivables during the six months ended December 31, 2019, our inventory increased by $1.6 million primarily related to the thoracic driver that we plan to launch later this third quarter of fiscal 2020.
Net cash provided by operating activities was $1.5 million for the six months ended December 31, 2018 primarily due to net income of $2.5 million offset by an increase in accounts receivable of $838,000, reflecting a slower payment trend from our largest customer.
Sales of our dental products and components declined for the three and six months ended December 31, 2019 compared to the corresponding periods of the prior fiscal year and we expect future declines in this area as we are no longer manufacturing dental products, but rather are simply selling remaining component inventory.
The research and development costs...Read more
In particular, we have experienced...Read more
During the six months ended...Read more
While we expect revenue growth...Read more
Gross profit increased by $669,000,...Read more
The increases relate primarily to...Read more
Costs relating to inventory and...Read more
The costs in the table...Read more
Actual results may differ from...Read more
Selling expenses for the three...Read more
Additionally, recurring revenue from two...Read more
19 During the quarter ended...Read more
These increases relate primarily to...Read more
Repair revenue increased $1.5 million...Read more
We anticipate sales to this...Read more
The effective tax rate for...Read more
Many other economic, competitive, governmental...Read more
We may experience variability in...Read more
We are focused on preserving...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Pro Dex Inc provided additional information to their SEC Filing as exhibits
Ticker: PDEX
CIK: 788920
Form Type: 10-Q Quarterly Report
Accession Number: 0001553350-20-000128
Submitted to the SEC: Thu Feb 06 2020 4:01:32 PM EST
Accepted by the SEC: Thu Feb 06 2020
Period: Tuesday, December 31, 2019
Industry: Surgical And Medical Instruments And Apparatus